MDCO - The Medicines Company A Buy On Inclisiran Data With Caveats
The Medicines Company (MDCO) currently has a market capitalization over $4 billion despite having consistently negative earnings, with the timing of profitability an unknown. The biotechnology company's value is dependent on its late-stage clinical drug inclisiran. The company previously had drugs for sale commercially but sold its older business in the first quarter of 2018 in order to concentrate on the inclisiran opportunity.
Investor optimism is now high, reflected in a 52-week high of $53.19 reached October 11, 2019, versus a 52-week low of $16.69 back in December 2019. Jeffries downgraded the stock